Engineered dry powders for the nose-to-brain delivery of transforming growth factor-beta
European Journal of Pharmaceutics and Biopharmaceutics · 2023-08 · 189 · 202-211
DOI: 10.1016/j.ejpb.2023.06.015 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Pharmaceutics and Biopharmaceutics, 2023-08. Verfasst von Chun Yuen Jerry Wong und 11 weiteren Autor:innen. Beteiligte Einrichtung: Respiratory Technology, Woolcock Institute of Medical Research, 431 Glebe Point Rd, Glebe, Sydney, NSW 2037, Australia. Hauptthemen laut MEDLINE: Transforming Growth Factor beta, Brain. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 46 Literaturangaben.
Abstract (Originalsprache)
Nose-to-brain delivery is increasing in popularity as an alternative to other invasive delivery routes. However, targeting the drugs and bypassing the central nervous system are challenging. We aim to develop dry powders composed of nanoparticles-in-microparticles for high efficiency of nose-to-brain delivery. The size of microparticles (between 250 and 350 µm), is desired for reaching the olfactory area, located below the nose-to-brain barrier. Moreover, nanoparticles with a diameter between 150 and 200 nm are desired for traveling through the nose-to-brain barrier. The materials of PLGA or lecithin were used in this study for nanoencapsulation. Both types of capsules showed no toxicology on nasal (RPMI 2650) cells and a similar permeability coefficient (Papp) of Flu-Na, which was about 3.69 ± 0.47 × 10-6 and 3.88 ± 0.43 × 10-6 cm/s for TGF-β-Lecithin and PLGA, respectively. The main difference was related to the location of deposition; the TGF-β-PLGA showed a higher drug deposition in the nasopharynx (49.89 ± 25.90 %), but the TGF-β-Lecithin formulation mostly placed in the nostril (41.71 ± 13.35 %).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Respiratory Technology, Woolcock Institute of Medical Research, 431 Glebe Point Rd, Glebe, Sydney, NSW 2037, Australia.
- Food, Nutrition, Health Program, Faculty of Land and Food Systems, The University of British Columbia, 213-2205 East Mall, Vancouver, BC, V6T 1Z4, Canada. Electronic address: baldelli@mail.ubc.ca.
- Respiratory Technology, Woolcock Institute of Medical Research, 431 Glebe Point Rd, Glebe, Sydney, NSW 2037, Australia; Macquarie Medical School, Faculty of Medicine, Health and Human Sciences, Macquarie University, Lev…
- Faculty of Dentistry, Department of Oral Biological and Medical Sciences, University of British Columbia, Vancouver, BC, Canada.
- Food, Nutrition, Health Program, Faculty of Land and Food Systems, The University of British Columbia, 213-2205 East Mall, Vancouver, BC, V6T 1Z4, Canada.
- St. Paul's hospital, 1081 Burrard St, Vancouver, BC V6Z 1Y6, Canada.
Zitieren
APA
Wong, C. Y. J., Baldelli, A., Gholizadeh, H., Oguzlu, H., Guo, Y., Xin Ong, H., Rodriguez, A. P., Singhera, G., Thamboo, A., Singh, A., Pratap-Singh, A., & Traini, D. (2023). Engineered dry powders for the nose-to-brain delivery of transforming growth factor-beta. European Journal of Pharmaceutics and Biopharmaceutics, 189, 202-211. https://doi.org/10.1016/j.ejpb.2023.06.015
Vancouver
Wong CYJ, Baldelli A, Gholizadeh H, Oguzlu H, Guo Y, Xin Ong H, et al. Engineered dry powders for the nose-to-brain delivery of transforming growth factor-beta. European Journal of Pharmaceutics and Biopharmaceutics. 2023;189:202-211. doi:10.1016/j.ejpb.2023.06.015
BibTeX
@article{Wong2023,
author = {Wong, Chun Yuen Jerry and Baldelli, Alberto and Gholizadeh, Hanieh and Oguzlu, Hale and Guo, Yigong and Xin Ong, Hui and Rodriguez, Athenea Pascual and Singhera, Gurpreet and Thamboo, Andrew and Singh, Anika and Pratap-Singh, Anubhav and Traini, Daniela},
title = {Engineered dry powders for the nose-to-brain delivery of transforming growth factor-beta},
journal = {European Journal of Pharmaceutics and Biopharmaceutics},
year = {2023},
volume = {189},
pages = {202--211},
doi = {10.1016/j.ejpb.2023.06.015}
}
EUVIMED